Voriconazole as Prophylaxis for Liver Transplant Recipients

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177788
First received: September 13, 2005
Last updated: August 14, 2012
Last verified: August 2012

September 13, 2005
August 14, 2012
September 2005
August 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00177788 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Voriconazole as Prophylaxis for Liver Transplant Recipients
Voriconazole as Prophylaxis for Liver Transplant Recipients

The study aims to determine if voriconazole prevents invasive fungal infections in liver transplant recipients. Endpoints would be: occurrence of invasive fungal infection and fungal colonization. Two groups will be compared: patients who received voriconazole as prophylaxis and historical controls who did not receive this prophylaxis.

The following variables will be followed: time and location of positive cultures, underlying diseases and severity of illness, voriconazole usage prophylactically, physical exam findings, laboratory and radiographical data, antimicrobial usage, microbiological data and resistance patterns, choice of antifungal drugs once organism identified, suspected source of infection, microbiological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, weight, ethnicity, and past medical history.

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

liver transplant patients receiving voriconazole

  • Fungemia
  • Mycoses
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
800
August 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients receiving a liver transplant at University of Pittsburgh Medical Center (UPMC) between January 1, 2001 and June 30, 2005.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00177788
IRB # 0508150
Yes
University of Pittsburgh
University of Pittsburgh
Pfizer
Principal Investigator: David Paterson, MD University of Pittsburgh
University of Pittsburgh
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP